Table 3.
Synergistic effects of fisetin with different anticancer drugs.
| Fisetin + Anticancer Drugs | Cancer | Finding of the Study | Refs. |
|---|---|---|---|
| Fisetin and sorafenib | Cervix cancer | The combination of sorafenib and fisetin synergistically caused the induction of apoptosis. The combined treatment of fisetin and sorafenib was obviously greater than sorafenib treatment alone based on the HeLa xenograft model. | [125] |
| Fisetin and cisplatin | Embryonal carcinoma | Fisetin enhanced the cytotoxicity of cisplatin. Fisetin and cisplatin increased cisplatin’s cytotoxicity at a dose that was 4 times lower than that needed by cisplatin monotherapy for the same effects of cytotoxicity. | [140] |
| Fisetin and cisplatin | Ovarian cancer | The combined treatment of Fisetin and cisplatin efficiently inhibits the proliferation of cancer cells, and the fragmentation of chromatin in cells occurred in the combination treatment. | [141] |
| Fisetin and cisplatin | Lung cancer | Fisetin efficiently increased the sensitivity of cancer cells to cisplatin, probably mediated via the inhibition of the abnormal activation of MAPK signaling pathways. | [142] |
| Fisetin and etoposide | Bone cancer | Fisetin:etoposide decreased the percentage of cells in the G1-phase and increased the percentage of cells in the G2-phase. | [131] |
| Fisetin and sorafenib | Skin cancer | The combination treatment (sorafenib + fisetin) more efficiently decreased the migration and invasion of BRAF-mutated melanoma cells. | [144] |
| Fisetin and 5-fluorouracil | Colon cancer | The treatment of PIK3CA-mutant cells with fisetin and 5-fluorouracil decreased the expression of PI3K, the phosphorylation of AKT and mTOR. Additionally, the combination of fisetin and 5-FU also decreased the total number of intestinal tumors. | [145] |
| Fisetin and geldanamycin | Colon cancer | Compared to fisetin treatment alone, geldanamycin and radicicol meaningfully increased the fisetin-induced cytotoxicity, produced a greater density of DNA ladder formation and enhanced the expression of cleaved caspase-3 as well as the PAPR protein | [146] |
| Fisetin and paclitaxel | Lung cancer | The switch from the cytoprotective autophagy to the autophagic cell death was concerned in the role of the synergistic action of both of the used compounds. | [105] |
| Fisetin and etoposide | Bone cancer | Cancer cells viability was decreased by 35% after exposure with fisetin. Fisetin showed synergistic cytotoxic effects with etoposide. | [147] |